Figure 2
From: Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Niraparib promoted tumor immune cell infiltration in both the BRCA-proficient SK6005 syngeneic and BRCA-deficient MDA-MB-436 NOG-EXL humanized tumor models (A) Representative images of CD4 and CD8 immunohistochemical staining in control- and niraparib-treated BRCA-proficient SK6005 tumors. (B–D) Quantification of the number of CD4+ cells, CD8+ cells and FoxP3+ cells per field upon niraparib treatment in BRCA-proficient SK6005 tumors. (E-G) Percentage of Ki67-positive CD4+ cells, CD8+ cells and FoxP3+ cells among the total CD3+ population by flow cytometry in humanized NOG-EXL MDA-MB-436 tumors. **p-value is less than 0.05 by Student’s t test.
